Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate

Zhen Xu, Heidi - Mansour, Tako Mulder, Richard Mclean, John Langridge, Anthony J. Hickey

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The objectives of this study were: systematic investigation of dry powder aerosol performance using standardized entrainment tubes (SETs) and lactose-based formulations with two model drugs; mechanistic evaluation of performance data by powder aerosol deaggregation equation (PADE). The drugs (IPB and FP) were prepared in sieved and milled lactose carriers (2% w/w). Aerosol studies were performed using SETs (shear stresses τs=0.624-13. 143N/m2) by twin-stage liquid impinger, operated at 60 L/min. PADE was applied for formulation screening. Excellent correlation was observed when PADE was adopted correlating FPF to τs. Higher τs corresponded to higher FPF values followed by a plateau representing invariance of FPF with increasing τs. The R2 values for PADE linear regression were 0.9905-0.9999. Performance described in terms of the maximum FPF (FPFmax: 15.0-37.6%) resulted in a rank order of ML-B/IPB>ML-A/IPB>SV-A/IPB>SV-B/IPB>ML-B/FP>ML-A/FP>SV-B/ FP>SV-A/FP. The performance of IPB was superior to FP in all formulations. The difference in lactose monohydrate carriers was less pronounced for the FPF in IPB than in FP formulations. The novel PADE offers a robust method for evaluating aerodynamic performance of dry powder formulations within a defined τs range.

Original languageEnglish (US)
Pages (from-to)3415-3429
Number of pages15
JournalJournal of Pharmaceutical Sciences
Volume99
Issue number8
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Ipratropium
Lactose
Aerosols
Powders
Pharmaceutical Preparations
Fluticasone
Linear Models

Keywords

  • Aerosolization performance
  • Aerosols
  • Dry powder inhaler
  • Emitted dose
  • Fine particle fraction
  • Physical characterization
  • Powder aerosol deaggregation equation
  • Pulmonary drug delivery
  • Shear stress
  • Standardized entrainment tubes

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Medicine(all)

Cite this

Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate : 2. Ipratropium bromide monohydrate and fluticasone propionate. / Xu, Zhen; Mansour, Heidi -; Mulder, Tako; Mclean, Richard; Langridge, John; Hickey, Anthony J.

In: Journal of Pharmaceutical Sciences, Vol. 99, No. 8, 2010, p. 3415-3429.

Research output: Contribution to journalArticle

@article{ea54e03eb50b41a49ffece5e11143de3,
title = "Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate",
abstract = "The objectives of this study were: systematic investigation of dry powder aerosol performance using standardized entrainment tubes (SETs) and lactose-based formulations with two model drugs; mechanistic evaluation of performance data by powder aerosol deaggregation equation (PADE). The drugs (IPB and FP) were prepared in sieved and milled lactose carriers (2{\%} w/w). Aerosol studies were performed using SETs (shear stresses τs=0.624-13. 143N/m2) by twin-stage liquid impinger, operated at 60 L/min. PADE was applied for formulation screening. Excellent correlation was observed when PADE was adopted correlating FPF to τs. Higher τs corresponded to higher FPF values followed by a plateau representing invariance of FPF with increasing τs. The R2 values for PADE linear regression were 0.9905-0.9999. Performance described in terms of the maximum FPF (FPFmax: 15.0-37.6{\%}) resulted in a rank order of ML-B/IPB>ML-A/IPB>SV-A/IPB>SV-B/IPB>ML-B/FP>ML-A/FP>SV-B/ FP>SV-A/FP. The performance of IPB was superior to FP in all formulations. The difference in lactose monohydrate carriers was less pronounced for the FPF in IPB than in FP formulations. The novel PADE offers a robust method for evaluating aerodynamic performance of dry powder formulations within a defined τs range.",
keywords = "Aerosolization performance, Aerosols, Dry powder inhaler, Emitted dose, Fine particle fraction, Physical characterization, Powder aerosol deaggregation equation, Pulmonary drug delivery, Shear stress, Standardized entrainment tubes",
author = "Zhen Xu and Mansour, {Heidi -} and Tako Mulder and Richard Mclean and John Langridge and Hickey, {Anthony J.}",
year = "2010",
doi = "10.1002/jps.22100",
language = "English (US)",
volume = "99",
pages = "3415--3429",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate

T2 - 2. Ipratropium bromide monohydrate and fluticasone propionate

AU - Xu, Zhen

AU - Mansour, Heidi -

AU - Mulder, Tako

AU - Mclean, Richard

AU - Langridge, John

AU - Hickey, Anthony J.

PY - 2010

Y1 - 2010

N2 - The objectives of this study were: systematic investigation of dry powder aerosol performance using standardized entrainment tubes (SETs) and lactose-based formulations with two model drugs; mechanistic evaluation of performance data by powder aerosol deaggregation equation (PADE). The drugs (IPB and FP) were prepared in sieved and milled lactose carriers (2% w/w). Aerosol studies were performed using SETs (shear stresses τs=0.624-13. 143N/m2) by twin-stage liquid impinger, operated at 60 L/min. PADE was applied for formulation screening. Excellent correlation was observed when PADE was adopted correlating FPF to τs. Higher τs corresponded to higher FPF values followed by a plateau representing invariance of FPF with increasing τs. The R2 values for PADE linear regression were 0.9905-0.9999. Performance described in terms of the maximum FPF (FPFmax: 15.0-37.6%) resulted in a rank order of ML-B/IPB>ML-A/IPB>SV-A/IPB>SV-B/IPB>ML-B/FP>ML-A/FP>SV-B/ FP>SV-A/FP. The performance of IPB was superior to FP in all formulations. The difference in lactose monohydrate carriers was less pronounced for the FPF in IPB than in FP formulations. The novel PADE offers a robust method for evaluating aerodynamic performance of dry powder formulations within a defined τs range.

AB - The objectives of this study were: systematic investigation of dry powder aerosol performance using standardized entrainment tubes (SETs) and lactose-based formulations with two model drugs; mechanistic evaluation of performance data by powder aerosol deaggregation equation (PADE). The drugs (IPB and FP) were prepared in sieved and milled lactose carriers (2% w/w). Aerosol studies were performed using SETs (shear stresses τs=0.624-13. 143N/m2) by twin-stage liquid impinger, operated at 60 L/min. PADE was applied for formulation screening. Excellent correlation was observed when PADE was adopted correlating FPF to τs. Higher τs corresponded to higher FPF values followed by a plateau representing invariance of FPF with increasing τs. The R2 values for PADE linear regression were 0.9905-0.9999. Performance described in terms of the maximum FPF (FPFmax: 15.0-37.6%) resulted in a rank order of ML-B/IPB>ML-A/IPB>SV-A/IPB>SV-B/IPB>ML-B/FP>ML-A/FP>SV-B/ FP>SV-A/FP. The performance of IPB was superior to FP in all formulations. The difference in lactose monohydrate carriers was less pronounced for the FPF in IPB than in FP formulations. The novel PADE offers a robust method for evaluating aerodynamic performance of dry powder formulations within a defined τs range.

KW - Aerosolization performance

KW - Aerosols

KW - Dry powder inhaler

KW - Emitted dose

KW - Fine particle fraction

KW - Physical characterization

KW - Powder aerosol deaggregation equation

KW - Pulmonary drug delivery

KW - Shear stress

KW - Standardized entrainment tubes

UR - http://www.scopus.com/inward/record.url?scp=77955105106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955105106&partnerID=8YFLogxK

U2 - 10.1002/jps.22100

DO - 10.1002/jps.22100

M3 - Article

C2 - 20222025

AN - SCOPUS:77955105106

VL - 99

SP - 3415

EP - 3429

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 8

ER -